Tag: scar

Between 2018 and 2023, Dr Ivan Puah treated over 550 cases, addressing unique challenges in Singapore's multi-ethnic population. His study included diverse case profiles....

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of AeroVironment, Inc. (NASDAQ: AVAV) between June 25, 2025 and March 10, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026.

In a recent video Q&A, board-certified plastic surgeon Dr. Pane breaks down the differences between tummy tuck, revision surgery, and liposuction, helping patients choose...

New arrivals mark major step in Kaiser Permanente's expanded relationships with HCA HealthONE and CommonSpirit Health DENVER, July 7, 2025 /PRNewswire/ -- Kaiser Permanente welcomed...

Starting today, applications are open for the Maesa Magic Incubator Class of 2026. NEW YORK, June 25, 2025 /PRNewswire/ -- Maesa, the Next-Gen Beauty Company,...

Findings from 16-week trial of novel compression patch will be shared for the first time at the 85th Scientific Sessions of the American Diabetes...

Aesthetic Procedures Close to 38 Million in 2024. MOUNT ROYAL, N.J., June 20, 2025 /CNW/ -- The International Society of Aesthetic Plastic Surgery (ISAPS) released the...

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

SEOUL, South Korea, June 7, 2025 /PRNewswire/ -- HIRONIC, a global leader in non-invasive medical aesthetic technology, has successfully hosted its inaugural 'HIRONIC Innovation...